{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:15:09Z","timestamp":1772165709268,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Pharma GmbH and Novartis Pharma AG funded this study"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Real-world evidence on experience and satisfaction of ofatumumab as a treatment option for relapsing multiple sclerosis (RMS) is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To present cumulative responses from a questionnaire related to first-hand experience of treating physicians on handling and convenience of ofatumumab therapy along with concerns related to COVID-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PERITIA was a multicentre survey conducted to collect responses from the ASCLEPIOS I\/II trial investigators from Europe via an online questionnaire.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty-six physicians (Germany,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200914; Spain,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912; Portugal,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910; Italy,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200910) completed the survey. Overall, 43% of the physicians considered the benefit-risk ratio of ofatumumab as very good. Over 93% were in favour of ofatumumab self-administration at home and the majority (83%) believed it to be completely true that self-administration of ofatumumab eases the burden for patients in terms of time. All investigators would like to potentially use anti-CD20 therapy as a long-term strategy. Even during the COVID-19 pandemic, physicians were in favour of a self-administration of MS therapy at home over other anti-CD20 therapy infusions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>European neurologists who were part of this survey considered the benefit-risk-ratio of ofatumumab as favourable and the monthly self-administered subcutaneous injections offering convenience for patients in the clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-023-03190-x","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T02:02:44Z","timestamp":1681092164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Assessment of the treating physicians\u2019 first-hand experience with handling and satisfaction of ofatumumab therapy: findings from the PERITIA survey conducted in Europe"],"prefix":"10.1186","volume":"23","author":[{"given":"Daniela","family":"Rau","sequence":"first","affiliation":[]},{"given":"Sara","family":"Eichau","sequence":"additional","affiliation":[]},{"given":"Giovanna","family":"Borriello","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Cerqueira","sequence":"additional","affiliation":[]},{"given":"Carola","family":"Wagner","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,4,10]]},"reference":[{"issue":"11","key":"3190_CR1","first-page":"313","volume":"4","author":"E Guthrie","year":"2007","unstructured":"Guthrie E. Multiple sclerosis: A primer and update. Adv Studies Pharm. 2007;4(11):313\u20137.","journal-title":"Adv Studies Pharm"},{"key":"3190_CR2","unstructured":"Multiple Sclerosis International Federation. Atlas of MS 3rd edition 2020-mapping multiple sclerosis around the world. Accessed May 6, 2021."},{"issue":"122","key":"3190_CR3","first-page":"251","volume":"22","author":"M Funaro","year":"2016","unstructured":"Funaro M, Messina M, Shabbir M, Wright P, Najjar S, Tabansky I, et al. The role of B cells in multiple sclerosis: More than antibodies. Discov Med. 2016;22(122):251\u20135.","journal-title":"Discov Med"},{"issue":"1","key":"3190_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2217\/nmt.15.67","volume":"6","author":"C Gasperi","year":"2016","unstructured":"Gasperi C, Stuve O, Hemmer B. B cell-directed therapies in multiple sclerosis. Neurodegener Dis Manag. 2016;6(1):37\u201347.","journal-title":"Neurodegener Dis Manag"},{"key":"3190_CR5","doi-asserted-by":"crossref","unstructured":"Smith P, Huck C, Wegert V, Schmid C, Dunn R. Low-dose, subcutaneous anti-CD20 therapy effectively depletes B cells and ameliorates CNS autoimmunity (P2.359). AAN.\u00a02017. https:\/\/n.neurology.org\/content\/88\/16_Supplement\/P2.359. Accessed 05 Apr 2023.","DOI":"10.1212\/WNL.88.16_supplement.P2.359"},{"issue":"3","key":"3190_CR6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1208\/s12248-012-9367-0","volume":"14","author":"WF Richter","year":"2012","unstructured":"Richter WF, Bhansali SG, Morris ME. Mechanistic determinants of biotherapeutics absorption following SC administration. AAPS J. 2012;14(3):559\u201370.","journal-title":"AAPS J"},{"issue":"7","key":"3190_CR7","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s11095-012-0708-6","volume":"29","author":"F Wu","year":"2012","unstructured":"Wu F, Bhansali SG, Law WC, Bergey EJ, Prasad PN, Morris ME. Fluorescence imaging of the lymph node uptake of proteins in mice after subcutaneous injection: molecular weight dependence. Pharm Res. 2012;29(7):1843\u201353.","journal-title":"Pharm Res"},{"key":"3190_CR8","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.3389\/fimmu.2019.02437","volume":"10","author":"MA Migotto","year":"2019","unstructured":"Migotto MA, Mardon K, Orian J, Weckbecker G, Kneuer R, Bhalla R, et al. Efficient distribution of a novel zirconium-89 labeled anti-CD20 antibody following subcutaneous and intravenous administration in control and experimental autoimmune encephalomyelitis-variant mice. Front Immunol. 2019;10:2437.","journal-title":"Front Immunol"},{"key":"3190_CR9","first-page":"P2.2","volume":"92","author":"JB Torres","year":"2019","unstructured":"Torres JB, Sealey M, Kneuer R, Leppert D, Roodselaar J, Weckbeckeret G, et al. Distribution and efficacy of ofatumumab and ocrelizumab in humanized-CD20 mice following subcutaneous or intravenous administration. Neurology. 2019;92:P2.2-052.","journal-title":"Neurology"},{"issue":"4","key":"3190_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s11481-019-09872-z","volume":"14","author":"C Huck","year":"2019","unstructured":"Huck C, Leppert D, Wegert V, Schmid C, Dunn R, Weckbecker G, et al. Low-dose subcutaneous anti-cd20 treatment depletes disease relevant b cell subsets and attenuates neuroinflammation. J Neuroimmune Pharmacol. 2019;14(4):709\u201319.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"20","key":"3190_CR11","doi-asserted-by":"publisher","first-page":"e1805","DOI":"10.1212\/WNL.0000000000005516","volume":"90","author":"A Bar-Or","year":"2018","unstructured":"Bar-Or A, Grove RA, Austin DJ, Tolson JM, VanMeter SA, Lewis EW, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis The MIRROR study. Neurology. 2018;90(20):e1805\u201314.","journal-title":"Neurology"},{"key":"3190_CR12","unstructured":"Savelieva M, Kahn J, Bagger M, D Meier, D Tomic, Leppert D, Wallstr\u00f6m E. Comparison of the B-cell recovery time following discontinuation of anti-CD20 therapies, ECTRIMS Online library.\u00a02017. https:\/\/journals.sagepub.com\/doi\/epub\/10.1177\/1352458517731285. Accessed 05 Apr 2023."},{"key":"3190_CR13","unstructured":"KESIMPTA\u00ae. Prescribing information. NJ: Novartis Pharmaceuticals Corp. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125326s070lbl.pdf. Accessed 05 Apr 2023."},{"key":"3190_CR14","unstructured":"KESIMPTA\u00ae. Summary of Product Characteristics. Novartis Pharma AG. 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kesimpta-epar-product-information_en.pdf. Accessed 05 Apr 2023."},{"issue":"6","key":"3190_CR15","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. ASCLEPIOS I and ASCLEPIOS II trial groups. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546\u201357.","journal-title":"N Engl J Med"},{"issue":"1","key":"3190_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12883-023-03100-1","volume":"23","author":"AP Ross","year":"2023","unstructured":"Ross AP, Besser C, Naval S, Stoneman D, Gaunt H, Barker N. Patient and nurse preferences for the Sensoready\u00ae autoinjector pen versus other autoinjectors in multiple sclerosis: Results from a multicenter survey. Presented at ACTRIMS 2021 (Virtual). BMC Neurol. 2023;23(1):85.","journal-title":"BMC Neurol"},{"issue":"6","key":"3190_CR17","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1177\/13524585211044479","volume":"28","author":"A Bar-Or","year":"2022","unstructured":"Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, et al. Rapid and sustained b-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2022;28(6):910\u201324.","journal-title":"Mult Scler"},{"issue":"3","key":"3190_CR18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40263-021-00804-1","volume":"35","author":"AT Reder","year":"2021","unstructured":"Reder AT, Centonze D, Naylor ML, Nagpal A, Rajbhandari R, Altincatal A, et al. COVID-19 in patients with multiple sclerosis: Associations with disease-modifying therapies. CNS Drugs. 2021;35(3):317\u201330.","journal-title":"CNS Drugs"},{"issue":"6","key":"3190_CR19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1001\/jamaneurol.2021.0688","volume":"78","author":"A Salter","year":"2021","unstructured":"Salter A, Fox RJ, Newsome SD, Halper J, Li DKB, Kanellis P, et al. Outcomes and risk factors associated with SARS-CoV-2 infection in a north american registry of patients with multiple sclerosis. JAMA Neurol. 2021;78(6):699\u2013708.","journal-title":"JAMA Neurol"},{"issue":"3","key":"3190_CR20","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1007\/s00415-021-10836-8","volume":"269","author":"M Filippi","year":"2022","unstructured":"Filippi M, Danesi R, Derfuss T, Duddy M, Gallo P, Gold R, et al. Early and unrestricted access to high-efficacy disease-modifying therapies: A consensus to optimize benefits for people living with multiple sclerosis. J Neurol. 2022;269(3):1670\u20137.","journal-title":"J Neurol"},{"key":"3190_CR21","doi-asserted-by":"crossref","unstructured":"Gartner J, Hauser S, Bar-Or A, Montalban X, Cohen JA, Cross AH, et al. Benefit-risk of ofatumumab in treatment-naive early relapsing multiple sclerosis patients. Presented at Association of British Neurologists. Virtual Meeting. 2021;P113.","DOI":"10.1136\/jnnp-2022-ABN.438"},{"issue":"2","key":"3190_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2018.20588","volume":"321","author":"JWL Brown","year":"2019","unstructured":"Brown JWL, Coles A, Horakova D, Havrdova E, Izquierdo G, Prat A, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321(2):175\u201387.","journal-title":"JAMA"},{"issue":"9856","key":"3190_CR23","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829\u201339.","journal-title":"Lancet"},{"issue":"3","key":"3190_CR24","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221\u201334.","journal-title":"N Engl J Med"},{"issue":"5","key":"3190_CR25","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, SoelbergS\u00f8rensen P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416\u201326.","journal-title":"N Engl J Med"},{"issue":"8","key":"3190_CR26","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1080\/03007995.2019.1585779","volume":"35","author":"A Berardi","year":"2019","unstructured":"Berardi A, Siddiqui MK, Treharne C, Harty G, Wong SL. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: Adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches. Curr Med Res Opin. 2019;35(8):1371\u20138.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"3190_CR27","doi-asserted-by":"publisher","first-page":"e878","DOI":"10.1212\/NXI.0000000000000878","volume":"7","author":"A Signori","year":"2020","unstructured":"Signori A, Sacca F, Lanzillo R, Maniscalco GT, Signoriello E, Repice AM, et al. Cladribine vs other drugs in MS: Merging randomized trial with real-life data. Neurol Neuroimmunol Neuroinflamm. 2020;7(6):e878.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"3190_CR28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1517\/17425247.2013.763793","volume":"10","author":"A Bayas","year":"2013","unstructured":"Bayas A. Improving adherence to injectable disease-modifying drugs in multiple sclerosis. Expert Opin Drug Deliv. 2013;10(3):285\u20137.","journal-title":"Expert Opin Drug Deliv"},{"issue":"2","key":"3190_CR29","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1517\/17425247.2013.746311","volume":"10","author":"A Lugaresi","year":"2013","unstructured":"Lugaresi A. RebiSmart\u2122 (version 1.5) device for multiple sclerosis treatment delivery and adherence. Expert Opin Drug Deliv. 2013;10(2):273\u201383.","journal-title":"Expert Opin Drug Deliv"},{"key":"3190_CR30","doi-asserted-by":"crossref","unstructured":"Cross AH, Delgado S, Habek M, Davydovskaya M, Ward BJ, Cree BAC, et al. Outcomes of COVID-19 in patients with relapsing multiple sclerosis receiving ofatumumab: Data from the ALITHIOS study and post marketing surveillance. ePoster presented at Virtual ECTRIMS Congress 2021. P982. https:\/\/journals.sagepub.com\/doi\/epub\/10.1177\/13524585211047080. Accessed 05 Apr 2023.","DOI":"10.1212\/WNL.96.15_supplement.4123"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03190-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-023-03190-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-023-03190-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T06:48:52Z","timestamp":1702190932000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-023-03190-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,10]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3190"],"URL":"https:\/\/doi.org\/10.1186\/s12883-023-03190-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1404182\/v1","asserted-by":"object"}]},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,10]]},"assertion":[{"value":"28 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"From a legal or regulatory point of view, there is no obligation for all of the participating countries (Germany, Italy, Portugal and Spain) to submit this type of survey to an ethics committee. The questionnaire of the survey was subject to review and approval by the German Novartis \"Ethics, Risks & Compliance\" department. The Novartis \"Ethics, Risks & Compliance\" departments of all participating countries (Germany, Italy, Portugal and Spain) approved the conduct of the survey in the respective countries. All the participated physicians provided written informed consent to participate in the survey, to the collection and processing of their personal data and to the following agreement:<i>\u201cThe Contractual Partner acknowledges and recognizes that Novartis is member of the German Industry Association FSA (\"Voluntary Self-regulation for the Pharmaceutical Industry\") and this data collection complies with the industry standards and rules of the Industry Association, in particular the FSA Code of Conduct for the cooperation of the pharmaceutical industry with healthcare professionals.\u201d<\/i>There was no inclusion of patient data at any point in time throughout the survey. Therefore, no written patient informed consent is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DR received research support, travel grants, consultancy fees and speaker fees from Bayer Healthcare, Biogen, Celgene, Lilly, Merck, Novartis, Roche, Sanofi Genzyme, Teva and Zambon.SE received speaker honoraria and consultant fees from Biogen Idec, Novartis, Merck, Bayer, Sanofi Genzyme, Roche, Almirall and Teva.GB received consultant fee and grant for trip and Congress registration from Almirall, Biogen, Merck, Novartis, Roche, Teva, Sanofi Genzyme.JC has received compensation for participation in clinical trials, presence in advisory boards and as a speaker from Roche, Novartis, Sanofi, Almirall, Zambon, Biogen, Janssen, Merck and Bristol-Myers-Squibb and research funding from Biogen, Merck, Roche and Funda\u00e7\u00e3o BIAL.CW is an employee of Novartis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"147"}}